Navigation Links
Vanda Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 4, 2011
Date:7/20/2011

ROCKVILLE, Md., July 20, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the second quarter of 2011, on Thursday, August 4, 2011, before the market opens. A full text copy of the release will be disseminated at that time.

Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results at 10:00 AM ET on Thursday, August 4, 2011.  Also participating on the call will be James Kelly, Senior Vice President and Chief Financial Officer.  To participate in the conference call, dial the appropriate number below shortly before the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos.

The teleconference dial-in numbers are as follows:

Domestic callers 1-866-314-5232

International callers 1-617-213-8052

Participant Passcode 16117516

The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Thursday, August 4, 2011, beginning at 1:00 PM ET and will be accessible until Thursday, August 11, 2011, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 57140859.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders.  For more on
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014  BioPontis Alliance for Rare Disease ... announced today the creation of a joint venture ... the rare disease known as Charcot- Marie-Tooth (CMT) ... model earlier this month. Today,s partnership announcement with ... model where researchers and all CMT dedicated organizations ...
(Date:10/19/2014)... 2014 Große Pharmafirmen werden ... Problem dabei ist, dass große Pharmafirmen nicht willens ... teilen. Es war deshalb nicht einfach, ... umso mehr, dass es uns gelungen ist! Wir ... aufzuschreiben - mit einem Vorbehalt - einige haben ...
(Date:10/17/2014)... Oct. 17, 2014  Hanger, Inc. (NYSE: ... its results of operations for the quarter ended September ... market closes.  A conference call to discuss these results ... Friday, November 7, 2014. Those wishing to participate should ... November 14, 2014 by dialing 1-855-859-2056 and referencing Conference ...
Breaking Medicine Technology:The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3Vergleichsbericht zu Pharma-Kühlketten und CRT 2
... and CEO of Curemark, LLC , ( www.curemark.com ), ... of neurological diseases, moderated the neuroscience roundtable focused on autism ... Hauppauge, New York.   Sponsored by the State ... and Cold Spring Harbor Laboratories, the Life Sciences Summit focused ...
... Oct. 11 BioStorage Technologies, a global leader ... storage for the pharmaceutical and biotechnology industries, has ... sample preparation services, including sample aliquoting and nucleic ... need for comprehensive sample management continues to grow, ...
Cached Medicine Technology:Curemark Moderates Autism Panel at Life Sciences Summit 2010 2Curemark Moderates Autism Panel at Life Sciences Summit 2010 3Industry Leader BioStorage Technologies Broadens Sample Management Operations to Include Laboratory Sample Preparation Services 2
(Date:10/20/2014)... Collins, CO (PRWEB) October 20, 2014 ... dGH assays are the only imaging assays capable ... in a single test.  With these three dimensions ... their ability to detect the widest range of ... translocations—mutations usually missed by other genomic tools, including ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury law ... greater Phoenix area and across Arizona reports record demand ... automobile accidents. Statistics have indicated a steady increase in ... such, Hastings and Hastings has seen a steady increase ... have been injured through no fault of their own ...
(Date:10/19/2014)... 20, 2014 This report provides ... Seizure, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ... press releases. It also reviews key players involved ... special features on late-stage and discontinued projects. , ...
(Date:10/19/2014)... October 20, 2014 SweetDressy.com, a professional ... announced its promotion for long evening dresses . ... the special offer; the current discount is up to ... the industry pioneers in the fashion field. Its dress ... ladies dwelling in various parts of the world. All ...
Breaking Medicine News(10 mins):Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... News) -- Smoking boosts the risk of rheumatoid arthritis in ... risk factor for rheumatoid arthritis are among those most likely ... Researchers evaluated 605 black patients with rheumatoid arthritis and ... disease were slightly more likely to be former or current ...
... , MONDAY, Nov. 29 (HealthDay News) -- Genetics influence ... factors have the greatest impact in the summer, the results ... needed to maintain health and for strong bones, is naturally ... do not contain vitamin D unless it,s added by fortification. ...
... Neuroscientists at the Centre for Addiction and Mental Health (CAMH) ... type of highly targeted treatment for depression with a low ... time in their lives and is a leading cause of ... Nature Medicine found that coupling between two dopamine ...
... with GE Healthcare has produced the first results in humans ... presence and aggressiveness of prostate tumors in real time, by ... researchers have used this technology to conduct real-time metabolic imaging ... assessing the precise outlines of a tumor, its response to ...
... Mozes HealthDay Reporter , MONDAY, Nov. 29 (HealthDay ... tool is surging in emergency departments across the United States, ... to 2007, CT scan use in ERs increased by nearly ... concerns about the potential risks posed by more frequent exposure ...
... personal history of breast cancer should consider annual screening ... study presented today at the annual meeting of the ... Cancer Society (ACS) guidelines currently recommend annual screening with ... or with a strong family history indicating a lifetime ...
Cached Medicine News:Health News:Heavy Smoking May Double Rheumatoid Arthritis Risk in Blacks 2Health News:Neurological protein may hold the key to new treatments for depression 2Health News:New prostate cancer imaging shows real-time tumor metabolism 2Health News:New prostate cancer imaging shows real-time tumor metabolism 3Health News:New prostate cancer imaging shows real-time tumor metabolism 4Health News:CT Scan Use Surging in Hospital ERs 2Health News:CT Scan Use Surging in Hospital ERs 3Health News:CT Scan Use Surging in Hospital ERs 4Health News:Women with personal history of breast cancer should be screened with MRI 2
Antiseptic - Antibacterial Sudsing Cleanser...
... This requiring no water for ... hand hygiene to physically clean ... is either not an option ... allows you to return to ...
BETASEPT® Scrub 4% is for surgical handscrubbing, healthcare personnel hand-washing, preoperative patient prepping and general skin degerming....
... Scrub Care® Brand soaps, emulsions, washes ... ultimate in healthy skin care, helping ... skin healthy and soft even with ... not contain petroleum-based substances that can ...
Medicine Products: